Harrison Walker - US grants
Affiliations: | 2006-2008 | Neurology | University of Alabama, Birmingham, Birmingham, AL, United States |
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.
High-probability grants
According to our matching algorithm, Harrison Walker is the likely recipient of the following grants.Years | Recipients | Code | Title / Keywords | Matching score |
---|---|---|---|---|
2010 — 2014 | Walker, Harrison Carroll | K23Activity Code Description: To provide support for the career development of investigators who have made a commitment of focus their research endeavors on patient-oriented research. This mechanism provides support for a 3 year minimum up to 5 year period of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators. |
Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in Pd @ University of Alabama At Birmingham DESCRIPTION (provided by applicant): Deep brain stimulation (DBS) improves debilitating symptoms of movement disorders when conventional medical therapies, cell transplant strategies, and the delivery of gene-delivered growth factors fail. Despite the remarkable efficacy of DBS, its therapeutic mechanism remains unclear. There is controversy regarding whether the therapeutic effects of DBS are associated with inhibition or excitation of target neurons, the introduction of new activity into the network, or a combination of these mechanisms. Additionally, it is unclear why stimulus frequency plays an important role in the clinical response to therapy. The fundamental hypothesis of this proposal is that unilateral subthalamic nucleus (STN) DBS in PD alters neuronal activity in the bilateral basal ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation frequency. The following specific hypotheses will be tested in PD patients with unilateral STN DBS: (1) High frequency unilateral STN DBS in PD increases antidromic and orthodromic activation of contralateral STN neurons to a greater extent than low frequency stimulation. Preliminary findings of antidromic and orthodromic responses of STN neurons to contralateral DBS will be further explored using microelectrode recordings of STN neurons during contralateral high and low frequency STN DBS. Analyses will employ auto- and cross-correlograms and peristimulus rasters with histograms and Z-scores. (2) High frequency unilateral STN DBS in PD improves ipsilateral bradykinesia more than low frequency stimulation. Kinematic testing in the bilateral extremities of central and peripheral reaction time and movement time will be obtained at high and low stimulation frequencies during a wrist flexion/extension task and analyzed with ANOVA. (3) Unilateral STN DBS in PD alters activity in the ipsilateral premotor cortex. Magnetoencephalography (MEG) will measure the kinetics and localization of cortical magnetic fields evoked by high and low frequency STN DBS. Event detection, averaging, and peak detection will measure the kinetics of the evoked responses, and source localization will be calculated with single and two dipole models. As DBS is investigated for a wide variety of potential indications in neurology and psychiatry, there is a growing need to understand how it modulates brain activity to exert its clinical effects. Gaining such knowledge has the potential to improve the efficacy and safety of DBS in established indications and to guide future therapeutic innovations. PUBLIC HEALTH RELEVANCE: Deep brain stimulation (DBS) improves debilitating symptoms of movement disorders when conventional therapies fail. As DBS is investigated for a wide variety of potential indications in neurology and psychiatry, there is a growing need to understand how it modulates brain activity to exert its clinical effects. Gaining such knowledge has the potential to improve the efficacy and safety of DBS in established indications and to guide future therapeutic innovations. |
0.958 |
2016 — 2021 | Walker, Harrison Carroll | UH3Activity Code Description: The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2. |
Noninvasive Biomarkers to Advance Emerging Dbs Electrode Technologies in Parkinson's Disease @ University of Alabama At Birmingham ABSTRACT It is easy to underestimate the importance of normal movement in daily life, until that ability is altered or taken away by disease. Used in more than 150,000 patients worldwide, deep brain stimulation (DBS) is often an effective therapy for Parkinson's disease and other movement disorders, however symptomatic improvement varies substantially in individuals, across clinical trials, and over time. DBS is now proposed for earlier disease stages in Parkinson's disease and for new indications in neurology and psychiatry, potentially exposing larger numbers of patients to this invasive therapy. Emerging segmented or ?directional? DBS lead technology provides unprecedented opportunities to optimize clinical improvement and tolerability and to drive innovation in neuromodulation. We have pioneered new putative biomarkers that measure patient-specific cortical physiology elicited by DBS with combined electrocorticography and electroencephalography. Our findings demonstrate robust within-participant changes in cortical activation that distinguish effective versus ineffective stimulation sites. Here we will leverage this knowledge to guide efficient implementation of current steering with novel directional DBS lead technology. Our primary goal is to deliver innovative approach to tailor and optimize field shaping with novel directional lead technology to improve the efficacy and tolerability of DBS in patients with advanced Parkinson's disease. Additionally, our results will provide foundational knowledge (1) to better understand the concept of DBS dose; (2) to refine surgical targeting in real time; (3) and to inform emerging closed loop stimulation paradigms. |
0.958 |